Φορτώνει......
Treatment and relapse of interstitial lung disease in nivolumab‐treated patients with non–small cell lung cancer
Nivolumab, a human monoclonal antibody against programmed death‐1, is approved for the treatment of non–small cell lung cancer (NSCLC). Although nivolumab is generally well tolerated, it can cause interstitial lung disease (ILD), a rare but potentially fatal immune‐related adverse event. Currently,...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Cancer Sci |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
John Wiley and Sons Inc.
2021
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8019226/ https://ncbi.nlm.nih.gov/pubmed/33125784 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14715 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|